Search
Semaglutide Treatment Options
A collection of 194 research studies where Semaglutide is the interventional treatment. These studies are located in the United States . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
49 - 60 of 194
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +342 locations
Conditions: Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +389 locations
Conditions: Early Alzheimer´s Disease
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Not Yet Recruiting
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2025
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: Alcohol Use Disorder (AUD), HIV
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
Active Not Recruiting
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: FDRC, Costa Mesa, California +21 locations
Conditions: Diabetes Mellitus, Type 2
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Completed
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: North AL Health Res, LLC, Huntsville, Alabama +183 locations
Conditions: Non-alcoholic Steatohepatitis
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Recruiting
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: FDRC, Costa Mesa, California +46 locations
Conditions: Obesity
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Recruiting
This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. This study compares survodutide with another medicine called semaglutide. Survodutide is being developed to treat people with obesity.
Semaglutide is already used to treat people with obesity.
Parti... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/09/2025
Locations: Translational Research Institute for Metabolism and Diabetes, Orlando, Florida +1 locations
Conditions: Obesity
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Not Yet Recruiting
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adu... Read More
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/06/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Obesity/Therapy
Semaglutide for Helping Opioid Recovery
Recruiting
The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Active Not Recruiting
This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide.
This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in com... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: 840005, Birmingham, Alabama +13 locations
Conditions: Obesity
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Not Yet Recruiting
The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obesity
49 - 60 of 194